Hantz Financial Services Inc. Acquires 35,294 Shares of Enovis Co. (NYSE:ENOV)

Hantz Financial Services Inc. boosted its holdings in Enovis Co. (NYSE:ENOV) by 18.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 224,396 shares of the company’s stock after buying an additional 35,294 shares during the quarter. Hantz Financial Services Inc. owned approximately 0.40% of Enovis worth $9,660,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ENOV. Price T Rowe Associates Inc. MD increased its holdings in shares of Enovis by 88.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 381,118 shares of the company’s stock worth $23,802,000 after buying an additional 179,276 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in Enovis by 13.3% in the 2nd quarter. First Eagle Investment Management LLC now owns 284,596 shares of the company’s stock worth $12,864,000 after purchasing an additional 33,300 shares in the last quarter. Sei Investments Co. raised its position in Enovis by 50.9% in the second quarter. Sei Investments Co. now owns 223,358 shares of the company’s stock valued at $10,096,000 after purchasing an additional 75,317 shares during the last quarter. King Luther Capital Management Corp boosted its stake in shares of Enovis by 45.2% during the second quarter. King Luther Capital Management Corp now owns 177,862 shares of the company’s stock valued at $8,039,000 after purchasing an additional 55,385 shares in the last quarter. Finally, Chartwell Investment Partners LLC grew its holdings in shares of Enovis by 25.6% during the third quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company’s stock worth $8,681,000 after purchasing an additional 41,089 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

ENOV has been the topic of several recent research reports. Evercore ISI cut their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. JPMorgan Chase & Co. cut their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. JMP Securities assumed coverage on Enovis in a report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $67.00.

Enovis Price Performance

ENOV stock opened at $48.81 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company’s fifty day simple moving average is $43.18 and its 200 day simple moving average is $44.91. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of -22.29 and a beta of 1.91.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. During the same period in the previous year, the business earned $0.56 EPS. The firm’s revenue was up 21.0% compared to the same quarter last year. On average, analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.